Roswell Park–University of Chicago ovarian cancer translational program
Roswell Park Ovarian Cancer SPORE
Developing new immune-based treatments and biomarker tests for people with ovarian cancer, including an oncolytic virus combined with a CXCR4 blocker.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Roswell Park Cancer Institute Corp NIH-funded |
| Lab location | 1 site (Buffalo, United States) |
| Project ID | NIH-11146370 on NIH RePORTER |
What this research studies
This program brings together laboratory and clinical teams to turn discoveries into therapies for ovarian cancer patients. The work includes projects that study why ovarian tumors resist the immune system and seeks proteogenomic biomarkers in patient samples to predict response. One project tests an oncolytic virus engineered to deliver a CXCR4 antagonist alongside other translational efforts that bridge lab studies and clinical testing. The program also funds developmental awards and career enhancement to speed promising ideas toward patient trials.
Who could benefit from this research
Good fit: People with ovarian cancer—particularly those with recurrent or treatment-resistant disease who are willing to join clinical trials or provide tissue/blood samples—are ideal candidates to benefit or participate.
Not a fit: Individuals without ovarian cancer or patients who are medically ineligible for the program's trials and sample-collection procedures are unlikely to receive direct benefit.
Why it matters
Potential benefit: If successful, the program could produce more effective immunotherapies and tests to match patients to the treatments most likely to help them.
How similar studies have performed: Immune therapies and oncolytic viruses have shown promise in some cancers, but combining an oncolytic virus with CXCR4 blockade in ovarian cancer is relatively new and not yet proven.
Where this research is happening
Buffalo, United States
- Roswell Park Cancer Institute Corp — Buffalo, United States (Active)
Researchers
- Principal investigator: Moysich, Kirsten B. — Roswell Park Cancer Institute Corp
- Study coordinator: Moysich, Kirsten B.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.